Palisade Bio, Inc.
PALI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,394 | $1,675 | $950 | $2,084 |
| G&A Expenses | $1,528 | $1,168 | $1,360 | $1,298 |
| SG&A Expenses | $1,528 | $1,168 | $1,360 | $1,298 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,922 | $2,843 | $2,310 | $3,382 |
| Operating Income | -$2,922 | -$2,843 | -$2,310 | -$3,382 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $54 | $59 | $80 | $38 |
| Pre-Tax Income | -$2,868 | -$2,784 | -$2,230 | -$3,344 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,868 | -$2,784 | -$2,230 | -$3,344 |
| % Margin | – | – | – | – |
| EPS | -0.38 | -0.58 | -0.46 | -0.57 |
| % Growth | 34.5% | -26.1% | 19.3% | – |
| EPS Diluted | -0.38 | -0.58 | -0.46 | -0.39 |
| Weighted Avg Shares Out | 7,474 | 4,797 | 4,796 | 5,818 |
| Weighted Avg Shares Out Dil | 7,474 | 4,797 | 4,796 | 8,540 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $2 | $1 | $3 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$2,862 | -$2,781 | -$2,228 | -$3,382 |
| % Margin | – | – | – | – |